NYSEMKT: PTHS
Pelthos Therapeutics Inc Earnings Dates, Reports, Calls

Pelthos Therapeutics earnings were -$7.4M for the trailing 12 months ending Mar 31, 2025, with N/A growth year over year. The latest PTHS earnings report on Mar 31, 2025 announced Q1 2025 earnings of -$2.0M, up 2.1% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, PTHS reported annual earnings of -$8.0M, with 7.8% growth.

PTHS earnings history

Current Revenue
$0.0
Current Earnings
-$7.4M
Current Profit Margin
0%

PTHS Return on Equity

Insufficient data to display

PTHS undefined

Current Company
-419.2%
Current Industry
-2.5%
PTHS is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when PTHS announces earnings.

PTHS undefined

Current Company
168.48%
Current Industry
5.8%

PTHS vs Biotech Stocks

TickerEBITDAEarningsY/Y EarningsEPS
PTHS-$7.07M-$7.36MN/A-$12.40
TAOX-$12.17M-$12.97MN/A-$10.00
BCDA-$7.96M-$8.39MN/A-$2.33
CSCI-$15.36M-$17.56MN/A-$6.00
CYCN-$3.01M-$2.94MN/A-$1.16

Pelthos Therapeutics Earnings Reports & History FAQ

What were Pelthos Therapeutics's earnings last quarter?

Pelthos Therapeutics (NYSEMKT: PTHS) reported Q1 2025 earnings per share (EPS) of -$3.20, up 41.82% year over year. Total PTHS earnings for the quarter were -$1.97 million. In the same quarter last year, Pelthos Therapeutics's earnings per share (EPS) was -$5.50.

If you're new to stock investing, here's how to buy Pelthos Therapeutics stock.

Is Pelthos Therapeutics profitable or losing money?

As of the last Pelthos Therapeutics earnings report, Pelthos Therapeutics is currently losing money. Pelthos Therapeutics's net profit (also called net income) for the twelve months ending Mar 31, 2025 was -$7.36 million, a 18% decrease year over year.

What was PTHS's earnings growth in the past year?

As of Pelthos Therapeutics's earnings date in Q3 2025, Pelthos Therapeutics's earnings has grown year over year. PTHS earnings in the past year totalled -$7.36 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.